EORTC Bladder Cancer Predictor

Clinical calculation support · Verify results before clinical use

Recurrence and progression risk assessment

Enter the six clinical and pathological factors to estimate 1-year and 5-year risks.

6 Factors
Number of tumors

Number of tumors

Number of tumors identified at the current assessment.

Maximum tumor diameter

Maximum tumor diameter

Use the largest tumor diameter measured in centimeters.

Prior recurrence rate

Prior recurrence rate

For a recurrent tumor, use the prior recurrence frequency.

Tumor T category

Tumor T category

This original model applies to non-muscle-invasive Ta/T1 disease.

Concomitant carcinoma in situ (CIS)

Concomitant carcinoma in situ (CIS)

CIS present in addition to the papillary tumor.

Tumor grade (WHO 1973)

Tumor grade (WHO 1973)

Select the historical WHO 1973 grade, not the WHO 2004/2022 grade.

Reset

About the EORTC risk tables

The EORTC 2006 model estimates recurrence and progression after transurethral resection in patients with non-muscle-invasive Ta/T1 bladder cancer. It was derived from 2,596 patients enrolled in seven EORTC trials and uses six clinical and pathological factors.

The model uses tumor number, tumor size, prior recurrence rate, T category, concomitant carcinoma in situ, and tumor grade according to the 1973 WHO classification. It reports separate point totals and risk estimates for recurrence and progression.

Point allocation used by this calculator

FactorCategoryRecurrenceProgression
Number of tumorsSingle00
2–733
8 or more63
Tumor diameterLess than 3 cm00
3 cm or greater33
Prior recurrence ratePrimary00
One or fewer per year22
More than one per year42
T categoryTa00
T114
Concomitant CISNo00
Yes16
WHO 1973 gradeG100
G210
G325

Risk bands and estimated probabilities

OutcomePoints1 year5 years
Recurrence015%31%
Recurrence1–424%46%
Recurrence5–938%62%
Recurrence10–1761%78%
Progression00.2%0.8%
Progression2–61%6%
Progression7–135%17%
Progression14–2317%45%

The progression score of 1 is not expected from the listed point allocations. The implementation handles this edge case conservatively in the lowest progression band to prevent an erroneous assignment to the highest band.

Important applicability considerations

  • The EORTC 2006 tables use the WHO 1973 grading system and were derived from patients in clinical trials.
  • Risk estimates may not calibrate well to every contemporary treatment setting, including patients receiving intravesical BCG. The EAU guideline distinguishes the 2006 EORTC model from later EORTC and CUETO models for BCG-treated patients.
  • Do not use this calculator as a substitute for current guideline-based NMIBC risk grouping, pathology review, or individualized clinical judgment.

References

Sylvester RJ, van der Meijden APM, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. European Urology. 2006;49(3):466–477. doi:10.1016/j.eururo.2005.12.031 · PMID: 16442208
European Association of Urology (EAU). EAU Guidelines on Non-muscle-invasive Bladder Cancer, section on predicting disease recurrence and progression. Consult the current guideline for model selection and applicability. Official EAU guideline chapter
Clinical disclaimer: This calculator provides estimates from the original EORTC risk tables and is intended to support, not replace, clinical assessment. It does not account for every prognostic feature or treatment context. Confirm histopathology and grading, review prior and planned intravesical therapy, and use current guideline recommendations when making surveillance and treatment decisions.